Ratings by JPMorgan (Priyanka Grover)

More Stocks Rated by JPMorgan
Date CompanySymbol Type Rating
(Past)		 PT
(Past)		 Start $
(End $)		 % Chg. Details
10/15/2026 Rhythm Pharmaceuticals RYTM Maintain Overweight
(Overweight)		  
 		   Details
10/14/2026 Arcus Biosciences RCUS New Coverage Overweight
(N/A)		 24.34
(22.12)		 -9.12% Details
10/8/2026 Neurogene NGNE New Coverage Overweight
(N/A)		 25.45
(23.25)		 -8.64% Details
10/1/2026 Enliven Therapeutics ELVN New Coverage Overweight
(N/A)		 46.51
(37.32)		 -19.76% Details
10/1/2026 Kura Oncology KURA New Coverage Overweight
(N/A)		 10.81
(9.08)		 -16% Details
8/18/2026 Mereo BipPharma Group MREO Downgrade Underweight
(Neutral)		 0.31
(0.30)		 -3.23% Details
8/18/2026 Nuvation Bio Inc NUVB New Coverage Overweight
(N/A)		 6.22
(4.45)		 -28.46% Details
8/14/2026 BridgeBio Oncology Therapeutics, In BBOT Maintain Overweight
(Overweight)		  
 		   Details
8/14/2026 Relay Therapeutics RLAY Maintain Overweight
(Overweight)		  
 		   Details
8/7/2026 Rhythm Pharmaceuticals RYTM Maintain Overweight
(Overweight)		  
 		   Details
7/27/2026 Rhythm Pharmaceuticals RYTM New Coverage Overweight
(N/A)		 102.66
(86.17)		 -16.06% Details
7/8/2026 BridgeBio Oncology Therapeutics, In BBOT New Coverage Overweight
(N/A)		 8.41
(2.82)		 -66.47% Details
7/8/2026 Relay Therapeutics RLAY New Coverage Overweight
(N/A)		 18.90
(16.28)		 -13.86% Details
4/30/2026 Recursion Pharmaceuticals RXRX Maintain Overweight
(Overweight)		  
 		   Details
3/23/2026 Mereo BipPharma Group MREO Downgrade Neutral
(Overweight)		 0.36
(0.31)		 -13.89% Details
12/17/2025 Recursion Pharmaceuticals RXRX Upgrade Overweight
(Neutral)		 4.20
(3.47)		 -17.38% Details
8/25/2025 Mereo BipPharma Group MREO Maintain Overweight
(Overweight)		  
 		   Details
7/10/2025 Mereo BipPharma Group MREO Maintain Overweight
(N/A)		  
 		   Details
3/27/2025 Mereo BipPharma Group MREO New Coverage Overweight
(N/A)		 2.35
(0.36)		 -84.68% Details